1. Home
  2. BDSX vs ACIU Comparison

BDSX vs ACIU Comparison

Compare BDSX & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Biodesix Inc.

BDSX

Biodesix Inc.

HOLD

Current Price

$29.08

Market Cap

276.2M

Sector

Health Care

ML Signal

HOLD

Logo AC Immune SA

ACIU

AC Immune SA

HOLD

Current Price

$2.83

Market Cap

247.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BDSX
ACIU
Founded
2005
2003
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Precision Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
276.2M
247.6M
IPO Year
2020
2015

Fundamental Metrics

Financial Performance
Metric
BDSX
ACIU
Price
$29.08
$2.83
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
2
Target Price
$32.50
$10.00
AVG Volume (30 Days)
81.3K
128.3K
Earning Date
05-04-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$88,499,000.00
N/A
Revenue This Year
$25.26
$706.75
Revenue Next Year
$19.15
$321.13
P/E Ratio
N/A
N/A
Revenue Growth
24.08
N/A
52 Week Low
$5.26
$2.10
52 Week High
$31.31
$4.00

Technical Indicators

Market Signals
Indicator
BDSX
ACIU
Relative Strength Index (RSI) N/A N/A
Support Level N/A N/A
Resistance Level N/A N/A
Average True Range (ATR) 0.00 0.00
MACD 0.00 0.00
Stochastic Oscillator 0.00 0.00

Price Performance

Historical Comparison
BDSX
ACIU

About BDSX Biodesix Inc.

Biodesix Inc is a diagnostic solutions company with a focus on lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources: providing diagnostic testing services associated with blood-based lung and COVID tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties, as well as the development and commercialization of companion diagnostics.

About ACIU AC Immune SA

AC Immune SA is a clinical stage biopharmaceutical company advancing a portfolio of programs strategically focused on pioneering Precision Medicine for neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company has one segment. The company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.

Share on Social Networks: